• Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion
• Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments
• As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces.

In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://ibn.fm/1UQMB).

At the same time, the psychedelic drugs market is also projected to reach $6.85 billion by 2027. That forecast is based on increased incidences of mental health disorders as well as growing acceptance of psychedelic drugs. The expected proliferation of psychedelics comes from continued research interest from major academic institutions (http://ibn.fm/g75oV).

Cybin is committed to advancing research and development (R&D) through its intellectual property portfolio in the psychedelic, pharmaceutical and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.

The company’s business model is structured around two wholly owned divisions across the pharmaceutical and nutraceutical sector: Serenity Life Sciences and Nature’s Journey Inc. Serenity Life Sciences is focused on advancing R&D of psilocybin-based pharmaceutical products. Psilocybin, a naturally occurring, non-habit-forming psychedelic compound derived from mushrooms, is experiencing a strong research revival.

Studies show promising results in the treatment of a number of mental health conditions such as anxiety, depression, PTSD, addiction, eating disorders, ADHD and other conditions (http://ibn.fm/2vOww). Cybin views mushroom-derived psychedelic medicines as brain boosters potentially capable of breaking negative thought patterns. Studies indicate that retraining thought processes with low doses of psychedelics help with mental health conditions affecting hundreds of millions of people worldwide.

Cybin’s Nature’s Journey Inc. is focused on nonpsychedelic medical mushroom extracts. Consumer trend forecasts indicate that adaptogenic mushrooms are the next wave of super nutraceuticals. These products are designed to optimize overall health by enhancing mental wellness, immune-boosting detoxification and general well-being.

Cybin offers a robust, diversified business model with compelling growth opportunities in dual, complimentary sectors. Therefore, investors looking for high-potential investments in growing markets should take note of the company’s two-pronged approach to the psychedelic pharmaceutical and nutraceutical mushroom markets.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• The annual Precious Metals Summit at Beaver Creek is marking its 10th anniversary with its usual select slate of mining industry interests in an online format designed to be health-conscious amid the ongoing COVID-19 pandemic
• The conference began its three-day lineup of more than 250 company presenters, which began Tuesday, Sept. 15, concluding Sept. 17
• The Beaver Creek Precious Metals Summit is a by-invitation event that brings together significant investors and corporate executives with some of the world’s most prospective junior miners
• Concerns about the pandemic’s impact on economies worldwide have been accompanied by increased interest in gold and other precious metals, making the conference timelier than ever

The 10th annual Beaver Creek Precious Metals Summit launched Tuesday, Sept. 15 with a three-day lineup of over 250 mining companies presenting on their operations within a pandemic-excited market for gold, silver, and other key ores (http://ibn.fm/V2dPn).

The 2020 Precious Metals Summit Beaver Creek (Virtual) is one of the year’s key conferences in the sector, bringing together a by-invitation community of institutional investors, sell-side representatives and corporate executives from senior precious metals companies to meet and network with some of the world’s most prospective junior producers, explorers and developers.

Although the COVID-19 pandemic and ongoing corporate travel restrictions have impacted the business summit network, Beaver Creek is experienced in developing virtual contacts through webcasts. Last year’s summit at the Beaver Creek Resort in the Rockies west of Denver drew 14,332 webcast viewers during the week of the summit and another 14,434 individuals the following week (http://ibn.fm/H9vU0).

The 2019 summit included more than 400 buy-side delegates, and the average number of meetings per mining company jumped from 25 to 34, according to event organizers.

Kitco News reported recently that financing tracker Oreninc has noted some “exceptional” weeks for juniors this year as they’ve raised funds on the back of higher precious metal prices and easy access to capital. Those trends have accompanied economic battering by the worldwide contagion as it has led to huge job losses and restrictions on businesses’ in-person operations.

“[Juniors] have raised a lot of cash in the last few months. Everybody’s excited about the higher gold price,” Resources Opportunities podcast editor James Kwantes told Kitco (http://ibn.fm/ud2dm). “It will be interesting to see what happens when all the holds come off in the four-month paper. … Financings typically have a four-month hold placed on them. So if you buy into a private placement, you can’t do anything with the stock for four months. Typically, the company will try to generate news or hopefully make a deposit — make a discovery.”

The dozens of companies participating in this year’s Beaver Creek virtual summit will be available to participate in one-on-one meetings with qualified investors and corporate development teams.

The summit helps monied interests identify emerging growth companies with the potential for high returns in the future. The keynote and company presentations conclude Thursday, Sept. 17 with a panel discussing lessons learned from resource investing in a pandemic.

For more information visit the event’s website at www.PreciousSummit.com.

• “Mushrooms are having a moment,” reports “Forbes” article
• Sector projected to benefit from both users, investors
• Pure Extracts Technologies well positioned to partner with organizations eyeing development in both functional, psychedelic products

In what “Forbes” magazine is calling a “moment,” mushrooms are seeing rising popularity as growing numbers of people are interested in using the fungi as well as investing in them. This is great news for companies such as Pure Extract Technologies (“Pure Extracts”), a Canadian plant-based extraction company entering the functional medicinal mushroom space and collaborating in the psychedelic space

“Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades,” observes the article, titled “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health” (http://ibn.fm/10yfG). “In 2020, whether consuming, investing, or both, mushrooms are having a moment.” The article, which notes psychedelics’ potential to impact and improve mental health, mentions several upcoming events focused on psychedelic science, innovation and investment opportunities.

These events lend validity to the expanding psychedelic — and functional — mushroom market. Projections call for the global functional mushroom market to grow by a CAGR of 8.04% from 2019 through 2024 (http://ibn.fm/EVDxw), as functional mushrooms are used in a variety of health-care and pharmaceutical products. In addition, the depression medication market, where psychedelic mushrooms are showing strong potential, was projected to grow from $14.5 billion in 2014 to nearly $17.0 billion this year (http://ibn.fm/yoIoo).

Pure Extracts is well positioned to partner with organizations eyeing development in both functional and psychedelic products. The Company’s business model consists of three verticals: in-house brands; toll processing, or offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, or supplying products in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

In addition, Pure Extracts is applying for a Natural Health Products site license from Health Canada, which will enable the production and sales of functional mushroom products in an EU-GMP-compliant environment. Once EU-GMP certified, the products the Company produces in its 10,000-square-foot will qualify for international sales including in Germany where the importation regulations are among the strictest in the world. Finally, Pure Extracts is exploring several joint-development possibilities for Q4 2020 product launches.

Pure Extract Technologies Inc., headquartered in Pemberton British Columbia, is a soon-to-be public, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be a dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://ibn.fm/Pure

• Predictive Oncology presenting at upcoming LD 500 investor conference
• Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe
• Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://ibn.fm/42UBB). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.

LD Micro, the organizer of the LD 500 conference, was founded in 2006 with the purpose of providing an independent news resource for investors focusing on the microcap space. Initially a newsletter highlighting unique companies, the event has transformed itself into a series of influential conferences held annually– bringing together some of today’s most interesting smaller and micro-cap publicly listed companies and investors focusing on the space.

The LD 500 conference will be the company’s most ambitious event to date, hosting a selection of 500 of North America’s most promising micro-cap companies over a series of four days. The virtual event is set to include a series of keynote addresses and one-on-one meetings, where investors will be able to meet with corporate management teams to receive updates on ongoing corporate operations while posing queries of their own.

“We are delighted to be hosting our virtual event in order to showcase some of the truly unique names in micro-cap,” stated LD Micro president Chris Lahiji. “There are many people and companies who are unable to attend our live events, due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure.”

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. Through its subsidiary Helomics, POAI is bringing this cutting-edge technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors response to drugs. These models can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://ibn.fm/YWbtr).

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• 180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses
• The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later this year
• Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent
• 180 Life Sciences is completing phase 2b/3 clinical trials tackling fibrosis and inflammation-causing TNF substance aberrations

The sudden and surprise impact of the COVID-19 pandemic this year has drawn new attention to the bioreactive intricacies of the inflammatory process (http://ibn.fm/tWUgV) as medical scientists work feverishly to develop a clear response to the crisis that has killed some 900,000 people worldwide (as of September 2020) with millions more seriously affected (http://ibn.fm/U1hfy). Even before the virus began its sweep, inflammation was receiving critical attention from rheumatologists because of its significance to a wide array of diseases including arthritis, asthma, psoriasis, and many bowel diseases (http://ibn.fm/aF04C).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are scheduled to begin later this year, and two additional programs are in the preclinical stage.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), recently obtained bridge financing to acquire 180 Life Sciences, a process it expects to complete in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ATNF, according to a June news release (http://ibn.fm/YVZ2o).

KBLM has filed its amended S4 with the SEC on August 28, 2020 which is pending SEC clearance.

KBLM has valued 180 Life Sciences at $175 million at a time when analysts with Fortune Business Insights anticipate the anti-inflammatory therapeutics market will grow with a 9.3 percent CAGR through 2027 to generate revenues of $191.42 billion (http://ibn.fm/IEHIX).

The company’s phase 2b/3 clinical trials are tackling fibrosis and anti-TNF therapies related to early stage Dupuytren’s disease, frozen shoulder, and post-operative cognitive deficit, while preclinical studies are looking at liver fibrosis and nonalcoholic steatohepatitis.

Two other preclinical studies are tackling inflammatory pain and ulcerative colitis in ex-smokers. Developments in the anti-inflammatory therapeutics field aim to deliver medical responses that have less serious side effects than existing conventional treatments, through more effective targeting of specific conditions.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that are on the market and have improved the lives of millions of people and created companies that were later sold for billions of dollars. We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner,” KBL Merger Corp. CEO Dr. Marlene Krauss stated in the June news release.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

• The Movie Studio retains AdvisoryCloud to help identify, appoint company’s advisory board
• Growth of OTT media market in 2020 has led to significant growth in streaming audiences, leading to commensurate increase in demand for original content programming
• The Movie Studio has sought to capitalize on this trend by launching its own streaming platform, syndicating self-produced original content
• Coordination with AdvisoryCloud will assist MVES by providing it with highly experienced advisors adept at advancing companies’ growth trajectory

The Movie Studio (OTC: MVES), an independent Florida-based film studio, has announced that it has retained the services of AdvisoryCloud, a leading platform for advisors, to provide the company with advisory services as well as to assist in identifying and appointing expert advisors to The Movie Studio’s advisory board who could help add value to the company (http://ibn.fm/iCW5D).

AdvisoryCloud provides a platform enabling highly experienced executives to take a proactive approach in landing advisory work. With over 12,000 advisors on its platform, the company allows companies – ranging from start-ups to multi-national corporations – to assemble advisory boards of over 100 senior executives in a matter of weeks. In turn, companies are able to share their challenges and opportunities through a series of quarterly advisor briefings, receiving direct responses with unique advice, diverse suggestions and specific solutions from their highly specialized advisory team.

“One of the greatest resources available to any company proactively seeking advantages that can help their business succeed is the knowledge of advisors,” said AdvisoryCloud founder and CEO Jonathan Aspatore. “We are excited to connect The Movie Studio with a team of high-caliber advisors through our virtual advisory board services to provide the unique expertise and firsthand experiences needed to help take this company to the next level.”

The growth of the over-the-top media (“OTT”) sector, which encompasses audio, video and other media content delivered over the Internet, has witnessed a stunning surge in popularity over recent months – with the growth in OTT viewing rising by 196% year-over-year in April this year. The trend has proven to be highly favorable for The Movie Studio, and the company responded by launching its own eponymous platform featuring a wide variety of original content as well as movies drawn from a number of libraries acquired by the studio over the years.

The Movie Studio has capitalized on the ongoing growth in the online streaming industry over the past 24 months, which has seen the launch of a myriad of platforms—including the likes of Apple Plus, Disney Plus, HBO Max and NBC Universal’s Peacock—by licensing its original content through partnerships with Filmhub and BING Networks LLC.

This move has allowed the company to syndicate and monetize its motion pictures in a number of different global jurisdictions, further boosting their available revenue streams. Now, through its recently announced tie-up with AdvisoryCloud, The Movie Studio has sought to take the next step in developing its burgeoning film business.

“We look forward to utilizing AdvisoryCloud’s resources to provide critical evaluation of the company’s business mode, OTT platform and potential alignment of business verticals including potential M&A opportunities,” noted The Movie Studio CEO Gordon Scott Venters. “We are confident AdvisoryCloud could bring added value as a strategic partner regarding our business initiatives.”

For more information about the company, visit www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• The company continues to diversify product offerings to specialist sectors through its insurtech software
• Insurtech investments have grown steadily over the last decade, increasing pressure for change and innovation in the market
• InsuraGuest’s hospitality division recorded the most profitable month since inception despite challenges to the hospitality industry resulting from the global pandemic
• The company expects to launch a new Business Owner Policy insurtech portal by third quarter of 2020
• Further penetration of the vacation rental industry, which booked revenue of $57 million in 2019 and boasts a growth rate of 6.9%, provides InsuraGuest with tremendous growth potential

Insurtech company InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF) continues to disrupt the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple sectors. The company aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold.

Approximately $16.5 billion has been invested in insurtech over the past decade, and the pressure for change and innovation in the insurance market continues to increase the pace of investment (http://ibn.fm/OwtGj). Insurance technology and innovation-driven startups like InsuraGuest are the driving force behind this increase, offering a unique combination of flexibility and technical skills that allows them to quickly pivot their platforms to meet the needs of different customers in different sectors.

One of the first sectors InsuraGuest has served with its insurtech platform is the hospitality market. The company utilizes its proprietary software platform to deliver specialized Hospitality Liability coverages to member hotels and vacation rental properties. With InsuraGuest Hospitality custom coverages, properties benefit from an additional layer of protection that prevents the need to make GL claims if an InsuraGuest-covered claim occurs.

The Hospitality Liability Policy was created to fill the gap that traveler’s insurance misses. People often assume that accidents that occur at a hotel or vacation rental are automatically covered by the property owner’s insurance, but that’s not always the case. InsuraGuest Hospitality provides coverage for accidental property damage, theft of the guest’s personal property while residing at the vacation rental property, as well as accidental medical expenses and accidental death and dismemberment.

InsuraGuest’s platform integrates with approximately 70 different hotel property management systems, including Hilton -ONQ, Marriott Fosse, Marriott Full Service, Oracle Opera, Springer-Miller Systems, Agilysys and Lightspeed GPS.

In July, the company partnered with Hostfully, a provider of end-to-end vacation rental property management software. InsuraGuest Hospitality Liability coverage can now be purchased by Hostfully’s client base of more than 2,500 vacation rental property managers.

In August, the company took steps to further expand its reach in the hotel sector by signing Swarts, Manning & Associates (“SMA”) for its agency/broker program. InsuraGuest will leverage SMA’s brokers and business network to access SMA’s hotel clients and integrate InsuraGuest’s insurtech software platform to deliver its hospitality liability coverages (http://ibn.fm/3vwLH).

Because InsuraGuest extends beyond hotels to the vacation rental industry, the growth potential in companies like Airbnb and VRBO is encouraging for the company’s investors. With over $50 billion in rental revenue in 2019 and a growth rate of 6.9%, the industry continues to grow as more people take advantage of the benefits vacations rentals offer (http://ibn.fm/JkuRs).

In addition, the hospitality division continues to prosper despite challenges presented by COVID-19. An increase in hotel stays during July resulted in the division seeing its most profitable month since inception.

As part of its commitment to diversify its insurance product offerings across multiple sectors, InsuraGuest announced the development of a new Business Owner Policy (“BOP”) insurtech portal, www.InsureThePeople.com. InsuraGuest expects to fully launch this new product offering to U.S. markets by third quarter of 2020. Insure the People will be powered by InsuraGuest’s insurtech platform, which will digitally deliver BOP policies to 130+ class codes, including retail, wholesale, mercantile, office and business service classes.

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Mullen Technologies’ EV SUV “serious competition” for Tesla’s Model Y
• MX-05 will have more mass-market appeal than competition
• NETE has definitive agreement with Mullen outlining stock-for-stock reverse merger

One of the most-recognized names in the electric vehicle (“EV”) world, Tesla (NASDAQ: TSLA), may be facing serious competition from several entrants into the EV space, including a lesser-known start-up, according to a recent “CarBuzz” report (http://ibn.fm/8kM9V). And Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group, may stand to benefit from the news.

“The Tesla Model Y is about to face some stiff competition from the Fisker Ocean and Mercedes EQA electric crossovers,” the Aug. 18 article stated. “But there’s another competitor you probably haven’t considered. California-based US startup Mullen Technologies is also joining the electric crossover bandwagon with the MX-05, the company’s second electric model following the Qiantu K50 electric sports car.”

The article goes on to note that the MX-05, a mid-size luxury SUV, features a 150-kWh solid-state battery that provides a driving range of more than 500 miles and will “inevitably have more mass-market appeal than the K50,” the article reads. “Based on results during independent testing, Mullen claims the battery technology will allow electric vehicles to travel 640 miles when cruising at 55 mph on a flat surface and 550 miles at a cruising speed of 75 mph. For comparison, the Tesla Model Y Long Range has 316 miles of range. Using a fast charger, the battery takes just 35 minutes to recharge.”

Last month, Net Element announced the execution of a definitive agreement to merge with Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company. That agreement means NETE is closely watching the development of the MX-05 SUV, which is slated for 2022 production.

“We believe our licensed solid-state battery technology should provide us with an advantage over many other companies in the EV space as it could have the ability to provide vehicle owners with significantly increased range from a single charge,” said Mullen CEO David Michery. “We believe the launch of our MX-05 will change the way that owners think about EVs and their capabilities.

“Modifying an existing, functional plant to create our vehicles will immediately catapult Mullen into very rare territory: an electric car manufacturer producing vehicles and distributing them throughout our internal network of dealers,” Michery continued. “Mullen has the ability to rise above the competition and be a true Tesla competitor, especially in the SUV market. Once the facilities are fully operational, Mullen will be able to integrate its proprietary solid-state battery technology into our vehicles and other consumer products.”

Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the United States and selected emerging markets.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Kaival Brands Innovations Group Inc. promotes innovative brand solutions. It is currently the exclusive global distributor for the first eco-friendly vapor product on the market, Bidi(TM) Stick.
• Manufactured by Bidi Vapor LLC, the Bidi(TM) Stick stands to revolutionize the vaping experience. It is a completely self-contained, disposable and recyclable product made with high-quality components and innovative technology.
• On September 8, 2020, Kaival Brands announced that Bidi Vapor LLC had submitted its Premarket Tobacco Product application to the U.S. Food and Drug Administration.
• Kaival Brands is also working to expand distribution of the Bidi(TM) Stick internationally into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.
• The partnership with Bidi Vapor has helped Kaival Brands expedite its growth, as the company reported $22.5 million in revenue in Q2 2020.

Kaival Brands Innovations Group (OTCQB: KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi(TM) Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi(TM) Stick.

Bidi(TM) Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi(TM) Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi(TM) Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (“PMTA”) to the U.S. Food and Drug Administration (“FDA”) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi(TM) Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi(TM) Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://ibn.fm/7EYu2).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi(TM) Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi(TM) Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://ibn.fm/ycLBD).

The positive results are primarily an effect of Bidi(TM) Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi(TM) Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://ibn.fm/DTqWH). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• PACR uses genetic technology to produce premium cannabis strains currently under supplied in regulated market
• Genetics-based cannabis cultivation optimizes specific factors including THC and CBD concentrations
• PACR is acquiring 100% interest in firm holding 250 acres of land in Fraser Valley, British Columbia
• Company is nearing completion of a 20,000 square foot cultivation facility to focus on genetic development, preservation and propagation of elite cultivars

Pac Roots Cannabis (CSE: PACR) uses a genetics-focused strategy to produce premium-quality, industry-leading cannabis strains that are not available in the regulated market. The Company’s innovative first-mover cultivation and production approaches are solidifying its reputation in the industry as a purveyor of genetically optimized premium-grade cannabis strains which are able to be tailored for a variety of purposes. With 100% of its next hemp harvest under sales contract at fair market value, the Company is poised to reap profits from up to 700,000 pounds of biomass scheduled to start harvest on October 15, 2020.

Genetics-based cannabis cultivation employs artificial selection and marker-assisted breeding, enabling cannabis producers to optimize for the end-use of the resulting crop. Qualities such as size, color, smell, density and texture factor heavily into how custom strains are differentiated—particularly those optimized for specific concentrations of tetrahydrocannabinol (“THC”) or cannabidiol (“CBD”). Besides giving cannabis cultivators the power to maximize product quality, the ability to genetically modify the structure of cannabis plants can also boost profitability through increased plant yields by selecting for larger and more numerous buds on each plant, ultimately enabling companies like Pac Roots to generate maximum quality and yield.

Through a joint venture with Rock Creek Farms, Pac Roots embarked on the 100-acre premium CBD hemp cultivation project after receiving a hemp cultivation license from Health Canada in May 2020. Following several weeks of preparation, planting of approximately 130,000 premium hemp CBD plants across two 50-acre parcels commenced in mid-June. Along with utilizing the rich native soil, the Company employed both traditional and customized farming techniques that include custom nutrients, systematic planting of stress-tested resilient cultivars, and advanced weed control measures along with complex irrigation systems to ensure each plant site is provided with optimal nutrients and spring water delivery.

Known widely as the “Napa Valley of the North”, the hemp plantation is located in the “Golden Mile” of the South Okanagan Valley, considered to be one of Canada’s best outdoor growing climates. Along with the Golden Mile project, Pac Roots is also in the process of acquiring all the issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley region of British Columbia—in addition to completing another 20,000 square foot cultivation facility in Lake Country, British Columbia.

Following the receipt of its cultivation license in Q4 2020, the facility will feature 7,600 square feet of growing space that will enable the Company to cycle through an elite line of over 350 unique, high-grade quality cultivars.

Cannabis-based products are gaining widespread acceptance in society across a wide range of demographics. As use-cases for CBD increase, the ability to enhance and customize various strains through their genetic makeup is becoming an important priority for industry cultivators. With a genetics-focused approach towards cannabis production, PACR is positioned to create an impact on the industry through its focus on the quality cultivation of industry-leading cannabis strains.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR